Nupur Nagarkatti
Postdoctoral Associate
Research & Publications
Biography
News
Coauthors
Selected Publications
- An Evaluation of Sex-Based Differences in Surrogate Consent for Older Adults Undergoing Surgical InterventionNagarkatti N, Miller S, Ahuja V, Schneider E, Mohanty S, Kodadek L. An Evaluation of Sex-Based Differences in Surrogate Consent for Older Adults Undergoing Surgical Intervention. Journal Of Surgical Research 2023, 288: 246-251. PMID: 37030182, DOI: 10.1016/j.jss.2023.02.041.
- Do Cultures From Percutaneously Drained Intra-abdominal Abscesses Change Treatment? A Retrospective ReviewEsposito A, Zhang Y, Nagarkatti N, Laird W, Coppersmith N, Reddy V, Leeds I, Mongiu A, Longo W, Hao R, Pantel H. Do Cultures From Percutaneously Drained Intra-abdominal Abscesses Change Treatment? A Retrospective Review. Diseases Of The Colon & Rectum 2022, 66: 451-457. PMID: 36538708, DOI: 10.1097/dcr.0000000000002644.
- Surrogate consent for surgery among older adult patientsMiller SM, Nagarkatti N, Ahuja V, Schneider EB, Mohanty S, Rosenthal RA, Kodadek LM. Surrogate consent for surgery among older adult patients. Surgery 2022, 172: 1748-1752. PMID: 36123180, DOI: 10.1016/j.surg.2022.08.015.
- Real-world evaluation of safety and effectiveness of dydrogesterone in the management of threatened abortionNagarkatti R, Mehra D, Mandal S, Dhawan A, Joshi P, Nagarkatti N, Chinda M, Jaiswal A. Real-world evaluation of safety and effectiveness of dydrogesterone in the management of threatened abortion. International Journal Of Reproduction Contraception Obstetrics And Gynecology 2022, 0: 2096. DOI: 10.18203/2320-1770.ijrcog20221833.
- Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sitesLi JY, Mutlu L, Tymon-Rosario J, Khadraoui W, Nagarkatti N, Hui P, Buza N, Lu L, Schwartz P, Menderes G. Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. Gynecologic Oncology Reports 2021, 39: 100913. PMID: 35005157, PMCID: PMC8715286, DOI: 10.1016/j.gore.2021.100913.
- A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instabilityBellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.
- DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivoTymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.
- In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinomaTymon-Rosario J, Bonazzoli E, Guglielmi A, Bellone S, Nagarkatti N, Zammataro L, Zeybek B, Harold J, Mauricio D, Clark M, Andikyan V, Huang G, Altwerger G, Menderes G, Azodi M, Ratner E, Schwartz P, Santin A. In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. Gynecologic Oncology 2021, 162: s186-s187. DOI: 10.1016/s0090-8258(21)01001-5.
- A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).Roque D, Bellone S, Siegel E, Buza N, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Schwartz P, Ratner E, Alexandrov L, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin A. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Journal Of Clinical Oncology 2021, 39: 5523-5523. DOI: 10.1200/jco.2021.39.15_suppl.5523.
- A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals Of Oncology 2021, 32: 1045-1046. PMID: 33932502, PMCID: PMC9465821, DOI: 10.1016/j.annonc.2021.04.013.
- Integrated mutational landscape analysis of uterine leiomyosarcomasChoi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2025182118. PMID: 33876771, PMCID: PMC8053980, DOI: 10.1073/pnas.2025182118.
- Robotic radical trachelectomy with an abdominally placed vaginal cerclage for containment of early stage cervical cancerTymon-Rosario J, Khadraoui W, Nagarkatti N, Menderes G. Robotic radical trachelectomy with an abdominally placed vaginal cerclage for containment of early stage cervical cancer. Gynecologic Oncology Reports 2020, 34: 100673. PMID: 33294577, PMCID: PMC7689334, DOI: 10.1016/j.gore.2020.100673.
- Robotic Radical Trachelectomy with an Abdominally Placed Vaginal CerclageTymon-Rosario J, Khadraoui W, Nagarkatti N, Menderes G. Robotic Radical Trachelectomy with an Abdominally Placed Vaginal Cerclage. Journal Of Minimally Invasive Gynecology 2020, 27: s17. DOI: 10.1016/j.jmig.2020.08.070.
- Robotic Resection of Deep Infiltrating Pelvic Sidewall Endometriosis and Concomitant NephrectomyBenabou K, Fernandez R, Nagarkatti N, Menderes G. Robotic Resection of Deep Infiltrating Pelvic Sidewall Endometriosis and Concomitant Nephrectomy. Journal Of Minimally Invasive Gynecology 2020, 27: s3-s4. DOI: 10.1016/j.jmig.2020.08.031.
- Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinomaBonazzoli E, Bellone S, Zammataro L, Gnutti B, Guglielmi A, Pelligra S, Nagarkatti N, Manara P, Tymon-Rosario J, Zeybek B, Altwerger G, Menderes G, Han C, Ratner E, Silasi DA, Huang GS, Andikyan V, Azodi M, Schwartz PE, Santin AD. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. Gynecologic Oncology 2020, 158: 769-775. PMID: 32600791, PMCID: PMC8253557, DOI: 10.1016/j.ygyno.2020.06.484.
- Robotic Low Anterior Resection and Partial Bladder Resection for Management of Locoregional Endometrial Cancer RecurrenceKhadraoui W, Tymon-Rosario J, Nagarkatti N, Menderes G. Robotic Low Anterior Resection and Partial Bladder Resection for Management of Locoregional Endometrial Cancer Recurrence. Journal Of Minimally Invasive Gynecology 2020, 28: 176-177. PMID: 32544562, DOI: 10.1016/j.jmig.2020.06.006.
- Battling Maternal Mortality Through Access to Primary Care Physicians [26F]Yadav G, Angraal S, Turrentine M, Nagarkatti N. Battling Maternal Mortality Through Access to Primary Care Physicians [26F]. Obstetrics And Gynecology 2020, 135: 67s-67s. DOI: 10.1097/01.aog.0000665156.75637.1b.
- Academic tweeting in #ObGyn. Where do we stand?Yadav G, Nagarkatti N, Rohondia S, Erfani H, Kilpatrick C, Turrentine M. Academic tweeting in #ObGyn. Where do we stand? Journal Of Perinatal Medicine 2019, 47: 867-870. PMID: 31494634, DOI: 10.1515/jpm-2019-0166.